The US Food and Drug Administration (USFDA) has issued a warning letter to Cipla’s Goa manufacturing facility.
In a regulatory filing with Stock Exchange, the company said, “Further to our earlier communication on the Goa manufacturing facility inspection conducted from September 16-27, 2019, by the US Food and Drug Administration (USFDA), the company has received a warning letter from USFDA.”
“It is committed to maintaining high standards of compliance and will work closely with the agency to comprehensively address all the observations,” the filing said.
